ACRV vs. LFCR, TRVI, GALT, RIGL, OMER, GBIO, OVID, ALIM, ATOS, and OGI
Should you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Lifecore Biomedical (LFCR), Trevi Therapeutics (TRVI), Galectin Therapeutics (GALT), Rigel Pharmaceuticals (RIGL), Omeros (OMER), Generation Bio (GBIO), Ovid Therapeutics (OVID), Alimera Sciences (ALIM), Atossa Therapeutics (ATOS), and Organigram (OGI). These companies are all part of the "pharmaceutical preparations" industry.
Acrivon Therapeutics (NASDAQ:ACRV) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings, valuation and community ranking.
In the previous week, Acrivon Therapeutics had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Acrivon Therapeutics and 2 mentions for Lifecore Biomedical. Acrivon Therapeutics' average media sentiment score of 1.32 beat Lifecore Biomedical's score of 0.95 indicating that Acrivon Therapeutics is being referred to more favorably in the media.
Acrivon Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.
Acrivon Therapeutics has higher earnings, but lower revenue than Lifecore Biomedical. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.
71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 7.3% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 14.6% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Acrivon Therapeutics received 22 more outperform votes than Lifecore Biomedical when rated by MarketBeat users. Likewise, 95.83% of users gave Acrivon Therapeutics an outperform vote while only 12.50% of users gave Lifecore Biomedical an outperform vote.
Acrivon Therapeutics presently has a consensus price target of $22.63, indicating a potential upside of 157.98%. Lifecore Biomedical has a consensus price target of $9.50, indicating a potential upside of 51.27%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Acrivon Therapeutics is more favorable than Lifecore Biomedical.
Lifecore Biomedical's return on equity of 0.00% beat Acrivon Therapeutics' return on equity.
Summary
Acrivon Therapeutics beats Lifecore Biomedical on 10 of the 16 factors compared between the two stocks.
Get Acrivon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acrivon Therapeutics Competitors List
Related Companies and Tools
